Introduction: is frequently downregulated in cancer and exhibits antitumorigenic properties, suggesting that miR-101 is a putative tumor suppressor. miR-101 is encoded at two loci in the human genome: 1p31.3 (miR-101-1) and 9p24.1 (miR-101-2). We sought to investigate miR-101 locus-specific deletions and genomic loss in the major subtypes of lung cancer. Methods: Analyses of high-resolution array comparative genomic hybridization and single-nucleotide polymorphism array data were performed to determine the DNA copy number status and deletion boundaries of miR-101-1 and miR-101-2 in seven independent cohorts that comprised 1236 lung cancer specimens and 20 lung carcinoma in situ samples. miR-101 expression was also investigated in lung cancer cell lines and tumors. Results: miR-101 loss at either genomic locus was identified in 29% of lung cancers analyzed and was associated with reduced miR-101 expression. Loss was more frequent at the 9p locus and occurred more often in NSCLC as opposed to small cell lung cancer. Lung carcinoma in situ also harbored miR-101 deletions, suggesting that genomic loss may be an early event in lung cancer development. Finally, miR-101 deletions on 9p were exclusive of CDKN2A deletions in several cases, providing evidence that loss of miR-101 is not merely a passenger of CDKN2A deletion. Conclusions: miR-101 genomic loss occurs frequently in NSCLC and may be an early event in lung tumorigenesis. DNA deletions likely represent a prominent molecular mechanism of miR-101 downregulation in NSCLC but not in small cell lung cancer.
MATERIALS AND METHODS
The DNA copy number status of miR-101-1 and miR-101-2 were determined for 261 lung tumors (169 adenocarcinomas [ACs], 92 squamous cell carcinomas [SCCs] ) and 20 lung carcinoma in situ (CIS) by tiling path array comparative genomic hybridization (aCGH) as previously described with BC Cancer Agency Research Ethics Board approval. 11 aCGH and single-nucleotide polymorphism (SNP) array data for an additional 975 lung cancer samples of diverse subtypes were compiled from five independent lung cancer datasets (Table  1) . SNP array data were analyzed using Partek Genomics Suite software (Partek Incorporated, St. Louis, MO). Copy number profiles for dbGaP (Database of Genotypes and Phenotypes) tumors were generated using matched nonmalignant profiles from the same individual as a reference, and Max-Planck Institute tumor profiles were generated using a pool of 59 nonmalignant tissues as a copy number baseline. Cell line profiles were generated using data for 72 cytogenetically normal HapMap individuals as a reference. 12 Copy number profiles for MSKCC and NCI aCGH data were generated using the segmentation algorithm, FAÇ ADE. 13 Data for each sample set were systematically screened to determine the frequency of miR-101 genomic loss at both loci using the following genomic coordinates (hg18) from the UCSC genome browser: miR-101-1 chr1:65296704-65296779 bp and miR-101-2 chr9:4840296-4840375 bp (http://genome.ucsc.edu/cgi-bin/hgGateway). Real-time quantitative polymerase chain reaction was performed to assess miR-101 expression levels in 25 NSCLC tumor normal pairs using TaqMan primers for miR-101 and U6 snRNA as an endogenous control (assay IDs: 002253 and 001973, respectively). Statistical analyses are described below.
RESULTS
To investigate the presence and locus-specific patterns of miR-101 genetic disruption, we first screened 261 tumors using high-resolution aCGH. Loss of either miR-101 locus (1p and/or 9p) was prevalent, occurring in 39% of these tumors. Although, loss at 9p (34%) and 1p (18%) were not mutually exclusive, 69% of the 103 tumors with miR-101 loss had loss at only one locus (Table 1) .
To verify that our findings were not limited to the British Columbia (BC) tumors alone, we repeated our analysis with data from five external cohorts. Deletion was detected in 24% of the 847 lung tumors and 48% of the 128 lung cancer cell lines (Table 1, Figure 1A ). Consistent with the BC patient cohort, the majority of cases (84%) showed deletion at only one miR-101 locus. Moreover, genomic loss of miR-101-2 (9p) was more prevalent than loss of miR-101-1 (1p) in each dataset.
To determine whether miR-101 gene deletion is equally common among the major subtypes of lung cancer, we first examined lung cancer cell lines. Genomic loss was more prevalent in NSCLC than in SCLC (Fisher's exact test, p ϭ 8.3 ϫ 10 Ϫ6 ) ( Figure 1B ). The frequency of loss was high in both AC and SCC subtypes of NSCLC (76% and 40%, respectively) but less frequent in SCLC (23%). miR-101 loss was also more prevalent in NSCLC tumors (28%) than SCLC tumors (12%) despite the limited number of SCLC tumors available for analysis (Fisher's exact test, p ϭ 0.048). As in cell lines, the frequency of miR-101 loss was not statistically different between AC and SCC tumors.
MiRNA expression data were available for 117 of the 128 lung cancer cell lines. miR-101 expression was significantly lower in cell lines with genomic loss versus those without (U test, p ϭ 0.0001). In 25 NSCLC tumors, miR-101 expression was also correlated with DNA copy number status as expression was significantly lower in tumors with genomic loss versus those without (U test, p ϭ 0.0289) ( Figure 2 ). Concordant with the subtype-specific DNA copy number findings, miR-101 expression was significantly higher in SCLC compared with NSCLC lines (U test, p Ͻ 0.0001) ( Figure 1C ). There was no significant difference in expression levels between AC and SCC subtypes in cell lines or tumors.
We also looked for clinicopathological associations with miR-101 genomic loss in one dataset with available clinical information. In the MSKCC tumors, 21 of 199 harbored miR-101 genomic loss. The limited power of this dataset likely contributed to our inability to identify any significant associations between miR-101 genomic loss and patient outcome, EGFR and KRAS mutation status, tumor recurrence, or smoking status.
Finally, we asked whether miR-101 genomic loss may be an early event in lung tumorigenesis. We examined 20 CIS cases and found that the majority (85%) harbored deletions at the 1p or 9p loci. Of the 17 cases with loss, 82% showed deletion at only one locus (Table 1, Figure 3 ).
DISCUSSION
miR-101 is a putative tumor suppressor often downregulated in cancers. [3] [4] [5] [6] 10 In prostate cancer, genomic loss is a recurrent event that results in miR-101 downregulation and consequential overexpression of its target gene, EZH2. 5 miR-101 DNA loss has been detected in acute lymphoblastic leukemias; gastric, breast, and prostate cancers; glioblastoma; and lung adenocarcinoma. 5 Interestingly, a recent report described genomic loss as a mechanism of miR-486 downregulation in gastric cancer, suggesting that DNA deletion may be a common mechanism of miRNA inactivation in a broad range of cancers. 14 In this study, we investigated several large lung cancer cohorts to determine whether (1) miR-101 DNA deletion is a prominent event in lung cancer, (2) COR-L105  NCI-H1437  NCI-H1975  NCI-H2347  NCI-H727  COR-L96CAR  LXF-289  NCI-H1395  A549  NCI-H1092  SBC-5  LK-2  NCI-H2170  NCI-H520  ABC-1  Calu-6  EKVX  NCI-H1573  NCI-H1693  NCI-H1755  NCI-H1792  NCI-H1838  NCI-H1993  NCI-H2009  NCI-H2030  NCI-H2087  NCI-H2126  NCI-H2228  NCI-H2291  NCI-H2342  NCI-H2405  PC-14  SK-LU-1  A427  NCI-H441  NCI-H650  LU-99A  HOP-92  IA-LM  LCLC-97TM1  NCI-H1299  NCI-H460  NCI-H810  NCI-H1703  Calu-1  NCI-H23  NCI-H522  NCI-H838  BEN  ChaGo-K-1  UMC-11  DMS-114  DMS-53  NCI-H1304  NCI-H1436  NCI-H2029  NCI-H510A  NCI-H64  NCI-H82  SHP- A recent study demonstrated frequent downregulation of miR-101 in NSCLC and demonstrated that re-expression had tumor suppressive effects, consistent with findings in other cancer types; however, the genetic mechanism driving miR-101 underexpression in these NSCLC tumors was not investigated. 10 We interrogated the frequency of miR-101 genomic loss in samples representing various lung cancer types. We screened a total of five independent lung cancer cohorts, analyzing 1236 lung cancer samples in addition to 20 lung CIS. Collectively, miR-101 genomic loss was observed in 30% of specimens analyzed. The high frequency of miR-101 deletion rivals the frequencies of genomic alteration to other well-known lung cancer genes such as EGFR, TITF1, KRAS, and LKB1 which are altered in approximately 10 to 40% of lung cancers. 15 Therefore, we conclude that miR-101 genomic loss is a prominent, recurrent event in lung cancer. Importantly, we found that miR-101 genomic loss was associated with low expression in both cell lines and tumors, suggesting that loss is a major mechanism of miR-101 downregulation in lung cancer.
It is becoming increasingly apparent that the histological subtypes of lung cancer exhibit distinct clinical behaviors that are likely driven by subtype specific molecular alterations. In light of this, we assessed the prevalence of miR-101 deletions in the three major types of lung cancer (AC, SCC, and SCLC). There was no significant difference in the prevalence of miR-101 deletions in AC and SCCs. However, we found that miR-101 genomic loss occurs preferentially in NSCLC as opposed to SCLC and that this difference is maintained at the expression level, as miR-101 expression was elevated in SCLC relative to NSCLC. This finding corroborates a previous observation in a smaller sample set in which miR-101 expression was higher in SCLC versus NSCLC cell lines. 16 Considering EZH2 is a known downstream target of miR-101, the difference in miR-101 copy number loss in NSCLCs and SCLCs, which corresponds to differential miR-101 expression, may suggest different mechanisms of EZH2 activation in these lung cancer types.
SCC is thought to evolve through a stepwise histopathological progression from abnormal lung dysplasia to CIS and finally to invasive cancer. To determine whether miR-101 DNA deletions are present in early-stage disease, we examined preinvasive lung lesions. Although our analysis was limited to 20 lung CIS samples due to the rarity of these specimens, we detected frequent miR-101 genomic loss, indicating that it could be an early event in the malignant transformation of bronchial epithelial cells. This observation is consistent with the finding that miR-101 is downregulated in the earliest stages of carcinogenesis. 17 miR-101 is coded for at genomic loci on chromosomes 1p (miR-101-1) and 9p (miR-101-2). Higher frequency of miR-101 loss at the 9p locus was observed in every dataset, which suggests that the 9p locus may be preferentially altered. Interestingly, miR-101-1 and miR-101-2 deletions occurred at only a single locus in 80% of all analyzed lung samples harboring deletions. However, we did not observe any rare events, such as homozygous deletions spanning either miR-101 locus in any of the datasets interrogated.
CDKN2A, 17.1 Mbp centromeric of the miR-101-2 locus, is the most well-known tumor suppressor located on chromosome 9p and is thought to be the primary driver gene of 9p DNA deletion events in cancer. As such, it could be argued that the high frequency of miR-101 loss observed is simply a side effect of large deletions targeting CDKN2A. However, in every cohort analyzed except for the SCLC tumors, we detected cases harboring miR-101-2 deletions in the absence of CDKN2A genomic loss. Thus, it is apparent that miR-101-2 and CDKN2A are not always codeleted, providing evidence that miR-101-2 deletions are not simply passengers of CDKN2A alterations.
In addition to providing biological insight into potential mechanistic differences in the major lung cancer types, miR-101 genomic loss and consequential downregulation have clinical implications. Although we did not observe any significant associations between miR-101 genomic loss and clinical features in the MSKCC dataset analyzed, which is limited in the number of cases with miR-101 deletion, low miR-101 expression in endometrial serous adenocarcinoma is significantly associated with poor survival. 18 miR-101 is also associated with therapeutic response in vitro, as enforced expression sensitizes cancer cells to chemo-and radiotherapies. 10, 19 Because of its tumor suppressive effects in vivo, it has been suggested that miR-101 could be developed as a therapeutic agent to target oncogenes such as EZH2. The findings of this and other studies provide sufficient evidence to warrant a prospective study of sufficient scale including the collection of well-annotated clinical information to investigate associations of miR-101 copy number loss and expression in a clinical setting. In summary, our analysis revealed miR-101 was preferentially lost in NSCLC compared with SCLC. Genomic loss was present in a 30% of lung cancers and CIS, making the frequency of miR-101 genetic disruption comparable to that of other established lung cancer genes such as EGFR. Integration of miR-101 copy number status and expression revealed a significant correlation, demonstrating that genomic loss causes a decrease in miR-101 expression. We also discovered miR-101 loss is an early event in NSCLC development and that miR-101 disruption predominantly occurs at the 9p locus only. In conclusion, we propose that genomic loss is a prominent subtype-specific mechanism of miR-101 disruption in NSCLC which may have an important role in NSCLC development.
